← Back to Clinical Trials
Recruiting NCT06741475

NCT06741475 Feasibility Study of Caregiver-Assist Strategy Training

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06741475
Status Recruiting
Phase
Sponsor Taipei Medical University
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2025-02-04
Primary Completion 2027-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Caregiver-Assist Strategy TrainingEducation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2025-02-04 with a primary completion date of 2027-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to examine the feasibility of delivering an innovative intervention, caregiver-assisted strategy training (CaST), targeting enhancing activity functions in community-dwelling adults after stroke. The main questions it aims to answer are: * Is CaST acceptable to stroke survivors with functional limitations? * Does CaST show positive effects on functional outcomes? Researchers will compare the CaST program to a control education program to investigate the interventional effect size for the selected stroke participants. Participants will: * Receive CAST or an education program 1 to 2 sessions per week until finishing 10 sessions. * Be assessed clinical outcomes at 4 times: pre-intervention, post-intervention, 3-month, and 6-month follow-up. * Be interviewed once after finishing their intervention.

Eligibility Criteria

Inclusion Criteria: * Being willing to provide informed consent * Diagnosis with ischemic and/or hemorrhagic stroke * Modified Rankin Scale (mRS) ranges from 2 to 4 * Rehabilitation frequency less than 3 days per week * Having a healthy caregiver Exclusion Criteria: * Undergoing palliative care * Major diseases or severe conditions influencing study participation, such as global aphasia, dementia, multiple organ failure, immobilization due to fracture, etc Moderate post-stroke cognitive impairment, with Montreal Cognitive Assessment score \<22 * Pre-stroke mRS \> 1 * Participating in other interventional study concurrently.

Contact & Investigator

Central Contact

Feng-Heng Chang, ScD

✉ ipc@tmu.edu.tw

📞 +886-2-66202589

Principal Investigator

Feng-Heng Chang, ScD

PRINCIPAL INVESTIGATOR

Graduate Institute of Injury Prevention and Control, Taipei Medical University

Frequently Asked Questions

Who can join the NCT06741475 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06741475 currently recruiting?

Yes, NCT06741475 is actively recruiting participants. Contact the research team at ipc@tmu.edu.tw for enrollment information.

Where is the NCT06741475 trial being conducted?

This trial is being conducted at New Taipei City, Taiwan, Taipei, Taiwan, Taipei, Taiwan.

Who is sponsoring the NCT06741475 clinical trial?

NCT06741475 is sponsored by Taipei Medical University. The principal investigator is Feng-Heng Chang, ScD at Graduate Institute of Injury Prevention and Control, Taipei Medical University. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology